Fig. 5b
From: IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience
Progression-free survival by mutational status (metastatic patients). In patients presenting with metastases, the PFS was 25% (95%CI: 1-65) in IDHmut and 16% (95%CI: 0.7-52) in IDHwt, (p=0.9126)